Brief: Ajanta Pharma Receives US FDA Establishment Inspection Report For Paithan Facility
BRIEF-Ajanta Pharma Receives US FDA Establishment Inspection Report For Paithan Facility July 2 (Reuters) - Ajanta Pharma Ltd AJPH.NS:
AJANTA PHARMA - RECEIVES US FDA ESTABLISHMENT INSPECTION REPORT FOR PAITHAN FACILITY
AJANTA PHARMA - PAITHAN FACILITY INSPECTION CLASSIFIED AS VOLUNTARY ACTION INDICATED
Source text: ID:nBSE4JNrCg
Further company coverage: AJPH.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Ajanta Pharma
See all newsIndia's Ajanta Pharma falls as analysts say growth to moderate in H2
Brief: Ajanta Pharma Limited Sept-Quarter Consol Net Profit 3.88 Billion Rupees
India's Ajanta Pharma jumps on June quarter profit jump
Brief: Ajanta Pharma June-Quarter Consol PAT 3.34 Billion Rupees
Brief: Ajanta Pharma Receives US FDA Establishment Inspection Report For Paithan Facility